This summary was created by AI, based on 1 opinions in the last 12 months.
Entrada Therapeutics, Inc. (TRDA-Q) is a pharma company that produces clinical stage drugs to aid the delivery of other therapeutics. With a portfolio of RNA based programs, the company is trading at 6x trailing earnings, under 1.5x book value, and supports a 32% return on equity. Additionally, it has growing cash reserves. Analysts recommend setting a stop-loss at $13 and aiming for $21, which represents an upside potential of 27%. The company's yield is at 0%, and analysts' price target is $21.50.
Entrada Therapeutics, Inc. is a American stock, trading under the symbol TRDA-Q on the NASDAQ (TRDA). It is usually referred to as NASDAQ:TRDA or TRDA-Q
In the last year, 1 stock analyst published opinions about TRDA-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Entrada Therapeutics, Inc..
Entrada Therapeutics, Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Entrada Therapeutics, Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Entrada Therapeutics, Inc. published on Stockchase.
On 2024-12-11, Entrada Therapeutics, Inc. (TRDA-Q) stock closed at a price of $19.9.
Our PAST TOP PICK with TRDA has achieved its target at $21. To remain disciplined, we recommend covering half the position at this time and trailing up the stop (from $13) to $16.